News

The data demonstrated that the RGB-286638 small molecule has potent activity against chronic myeloid leukemia (CML) in in vivo models that are resistant to imatinib (Gleevec) and to

The Phase Ib clinical trial is a double-blind, placebo-controlled study that will evaluate the tolerability, pharmacokinetics and viral kinetics of multiple, ascending doses of ANA598 over a period

Two pivotal 12-month studies met their primary endpoints, showing effects on exacerbation rates and pulmonary function (FEV1). Furthermore, two supporting six-month studies confirmed the efficacy of Daxas when

Therapure said that it will apply its experience and knowledge in cell culture and in the design and development of scaled-up biologic manufacturing processes to advance the initial

As CFO, Mr Coughlen will be responsible for all aspects of PolyRemedy’s finance function, including accounting, financial planning and analysis, and internal policy development. In addition, Mr Coughlen

Investors in the round included Piper Jaffray, Arnerich Massena & Associates, Medtronic, RiverVest Venture Partners, and other financial and strategic investors. Salient plans to use the net proceeds

Heilongjiang Tianlong Pharmaceutical Company, a subsidiary of China Sky One Medical, will purchase the breast drug for RMB10 million from Harbin Medical University. China Sky One Medical collaborated

The data demonstrated that tgAAC94, an investigational agent designed to inhibit activity of tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation, is well tolerated and may improve

Specially engineered to complement the existing offering of Cook embolization products and coils, MiraFlex high flow embodies the latest innovation in microcatheter technology designed to enhance traceability necessary